Literature DB >> 16789965

Fiduciary obligation in clinical research.

Paul B Miller1, Charles Weijer.   

Abstract

Mesh：

Year:  2006        PMID： 16789965     DOI： 10.1111/j.1748-720X.2006.00049.x

Source DB:  PubMed          Journal:  J Law Med Ethics        ISSN： 1073-1105            Impact factor:   1.718


× No keyword cloud information.
  16 in total

1.  Balancing scientific and community interests in community-based participatory research.

Authors:  David B Resnik; Caitlin E Kennedy
Journal:  Account Res       Date:  2010-07       Impact factor: 2.622

2.  Placebo Controlled Trials: Interests of Subjects versus Interests of Drug Regulators.

Authors:  Teguh Haryo Sasongko; Nor Hayati Othman; Nik Hazlina Nik Hussain; Yeong Yeh Lee; Sarimah Abdullah; Azlan Husin; Hans Van Rostenberghe
Journal:  Malays J Med Sci       Date:  2017-08-18

3.  Ethical issues for control-arm patients after revelation of benefits of experimental therapy: a framework modeled in neuroblastoma.

Authors:  Yoram Unguru; Steven Joffe; Conrad V Fernandez; Alice L Yu
Journal:  J Clin Oncol       Date:  2013-01-07       Impact factor: 44.544

4.  Who is the research subject in cluster randomized trials in health research?

Authors:  Andrew D McRae; Charles Weijer; Ariella Binik; Angela White; Jeremy M Grimshaw; Robert Boruch; Jamie C Brehaut; Allan Donner; Martin P Eccles; Raphael Saginur; Merrick Zwarenstein; Monica Taljaard
Journal:  Trials       Date:  2011-07-26       Impact factor: 2.279

5.  Ethical issues posed by cluster randomized trials in health research.

Authors:  Charles Weijer; Jeremy M Grimshaw; Monica Taljaard; Ariella Binik; Robert Boruch; Jamie C Brehaut; Allan Donner; Martin P Eccles; Antonio Gallo; Andrew D McRae; Raphael Saginur; Merrick Zwarenstein
Journal:  Trials       Date:  2011-04-20       Impact factor: 2.279

6.  It's Time: The Case for PrEP as an Active Comparator in HIV Biomedical Prevention Trials.

Authors:  Bridget Haire
Journal:  J Bioeth Inq       Date:  2014-07-20       Impact factor: 1.352

7.  Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP.

Authors:  Bridget Haire; Morenike Oluwatoyin Folayan; Catherine Hankins; Jeremy Sugarman; Sheena McCormack; Gita Ramjee; Mitchell Warren
Journal:  Dev World Bioeth       Date:  2013-05-31       Impact factor: 2.294

8.  Subjects' views of obligations to ensure post-trial access to drugs, care and information: qualitative results from the Experiences of Participants in Clinical Trials (EPIC) study.

Authors:  N Sofaer; C Thiessen; S D Goold; J Ballou; K A Getz; G Koski; R A Krueger; J S Weissman
Journal:  J Med Ethics       Date:  2009-03       Impact factor: 2.903

Review 9.  The clinical investigator-subject relationship: a contextual approach.

Authors:  David B Resnik
Journal:  Philos Ethics Humanit Med       Date:  2009-12-03       Impact factor: 2.464

10.  Genomic medicine and the "loss of chance" medical malpractice doctrine.

Authors:  Jennifer K Wagner; Michelle N Meyer
Journal:  HGG Adv       Date:  2021-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.